Insider Transactions in Q4 2020 at Igm Biosciences, Inc. (IGMS)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2020
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
178
+20.0%
|
-
|
|
Dec 31
2020
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
357
+0.38%
|
-
|
|
Dec 31
2020
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+50.0%
|
-
|
|
Dec 31
2020
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
357
+0.99%
|
-
|
|
Dec 31
2020
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
178
+0.32%
|
-
|
|
Dec 31
2020
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
446
+0.05%
|
-
|
|
Dec 31
2020
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
178
+0.01%
|
-
|
|
Dec 21
2020
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+49.62%
|
$2,750
$1.39 P/Share
|
|
Dec 17
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,618
-36.88%
|
$139,148
$86.1 P/Share
|
|
Dec 16
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
882
-16.74%
|
$78,498
$89.38 P/Share
|
|
Dec 16
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+32.18%
|
$0
$0.93 P/Share
|
|
Dec 11
2020
|
M Kathleen Behrens |
BUY
Open market or private purchase
|
Indirect |
44,444
+39.66%
|
$3,999,960
$90.0 P/Share
|
|
Dec 11
2020
|
Topsoe Holding A/S > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
111,111
+1.06%
|
$9,999,990
$90.0 P/Share
|
|
Dec 11
2020
|
Christina Teng Topsoe |
BUY
Open market or private purchase
|
Indirect |
111,111
+1.06%
|
$9,999,990
$90.0 P/Share
|
|
Dec 11
2020
|
Jakob Haldor Topsoe |
BUY
Open market or private purchase
|
Indirect |
111,111
+1.06%
|
$9,999,990
$90.0 P/Share
|
|
Dec 08
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,219
-1.04%
|
$110,929
$91.0 P/Share
|
|
Dec 07
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-0.58%
|
$49,032
$72.92 P/Share
|
|
Dec 07
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+1.58%
|
$1,900
$1.39 P/Share
|
|
Dec 02
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
608
-0.52%
|
$38,304
$63.15 P/Share
|
|
Dec 01
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-0.29%
|
$21,888
$64.22 P/Share
|
|
Dec 01
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
950
+0.8%
|
$950
$1.39 P/Share
|
|
Nov 13
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
132
+4.55%
|
$5,940
$45.45 P/Share
|
|
Nov 13
2020
|
Fred Schwarzer CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
291
+0.15%
|
$13,095
$45.45 P/Share
|
|
Nov 13
2020
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
42
+50.0%
|
$1,890
$45.45 P/Share
|
|
Nov 04
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
605
-0.52%
|
$30,250
$50.0 P/Share
|
|
Nov 02
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-0.29%
|
$17,940
$52.39 P/Share
|
|
Nov 02
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
950
+0.8%
|
$950
$1.39 P/Share
|
|
Oct 09
2020
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
535
+25.0%
|
-
|
|
Oct 09
2020
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
535
-100.0%
|
-
|
|
Oct 02
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,830
-1.55%
|
$133,590
$73.5 P/Share
|
|
Oct 01
2020
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
178
+25.0%
|
-
|
|
Oct 01
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,020
-0.85%
|
$77,520
$76.13 P/Share
|
|
Oct 01
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,850
+2.33%
|
$2,850
$1.39 P/Share
|
|
Oct 01
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Indirect |
1,000
-34.53%
|
$73,000
$73.59 P/Share
|
|
Oct 01
2020
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
357
+0.38%
|
-
|
|
Oct 01
2020
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+50.0%
|
-
|
|
Oct 01
2020
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
357
+1.0%
|
-
|
|
Oct 01
2020
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
178
+0.32%
|
-
|
|
Oct 01
2020
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
446
+0.05%
|
-
|
|
Oct 01
2020
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
178
+0.01%
|
-
|